RPS6KA2 and MAP2K1

Number of citations of the paper that reports this interaction (PubMedID 8939914)
45

Data Source:
HPRD (in vitro)

		RPS6KA2	MAP2K1
Description		ribosomal protein S6 kinase A2	mitogen-activated protein kinase kinase 1
Image		No pdb structure
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Cytosol	Nucleus Cytoplasm Mitochondrion Early Endosome Late Endosome Endoplasmic Reticulum Golgi Apparatus Microtubule Organizing Center Cytosol Plasma Membrane Focal Adhesion
	Molecular Function	Magnesium Ion Binding Protein Serine/threonine Kinase Activity Ribosomal Protein S6 Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Binding ATP Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Tyrosine Kinase Activity MAP-kinase Scaffold Activity Protein Binding ATP Binding Protein C-terminus Binding Protein Serine/threonine Kinase Activator Activity Protein N-terminus Binding Scaffold Protein Binding
	Biological Process	Protein Phosphorylation Signal Transduction Negative Regulation Of Cell Proliferation Intracellular Signal Transduction Positive Regulation Of Apoptotic Process Negative Regulation Of Cell Cycle	MAPK Cascade Activation Of MAPK Activity Protein Phosphorylation Chemotaxis Cell Cycle Arrest Signal Transduction Regulation Of Mitotic Cell Cycle Heart Development Negative Regulation Of Cell Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Peptidyl-threonine Phosphorylation Peptidyl-tyrosine Phosphorylation Cerebellar Cortex Formation Signal Transduction By Protein Phosphorylation Neuron Differentiation Keratinocyte Differentiation Thyroid Gland Development Stress-activated Protein Kinase Signaling Cascade Activation Of Protein Kinase Activity Regulation Of Stress-activated MAPK Cascade Positive Regulation Of Transcription, DNA-templated Thymus Development Regulation Of Axon Regeneration Cell Motility Positive Regulation Of Axonogenesis Bergmann Glial Cell Differentiation Face Development Trachea Formation Epithelial Cell Proliferation Involved In Lung Morphogenesis Placenta Blood Vessel Development Labyrinthine Layer Development ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Regulation Of Golgi Inheritance Cellular Senescence Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA Regulation Of Early Endosome To Late Endosome Transport
Pathways		ERK/MAPK targets CREB phosphorylation Senescence-Associated Secretory Phenotype (SASP) Senescence-Associated Secretory Phenotype (SASP) Recycling pathway of L1 CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling RSK activation RSK activation Gastrin-CREB signalling pathway via PKC and MAPK	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
Drugs			K-252a 5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		3-month functional outcome in ischaemic stroke (modified Rankin score) ( 30796134) Alzheimer's disease progression score ( 29860282) Bipolar disorder ( 31043756) Bipolar I disorder ( 31043756) Blood pressure (smoking interaction) ( 25189868) Dental caries ( 23259602) Inflammatory bowel disease ( 27569725 23128233) Pre-treatment viral load in HIV-1 infection ( 31219150) Smooth-surface caries ( 24556642) Urinary metabolite levels in chronic kidney disease ( 31959995) Waist circumference ( 28552196)	Prostate cancer ( 29892016) Testicular germ cell tumor ( 28604728 28604732)
Interacting Genes		12 interacting genes: BAD CREB1 FLNC FOS JUN L1CAM MAGI1 MAP2K1 MAPK1 MAPK3 SHANK1 TP53	43 interacting genes: ARAF BANP BIRC6 BRAF CASP9 CDK5 CPNE1 CPNE4 EGFR ELK1 EP300 GRB10 HNRNPD HRAS KAT7 KSR1 KSR2 LAMTOR3 MAP3K4 MAP3K8 MAPK1 MAPK14 MAPK3 MAPK8 MAPK8IP3 MYC PAK1 PARVA PEBP1 PEBP4 PLK3 PPARG PRKCI PRKCZ RAF1 RPS6KA2 RPS6KA4 TRAF3 TRAF6 TRIB1 UBE2I UBE2L3 WNK1
Entrez ID		6196	5604
HPRD ID		03403	01469
Ensembl ID		ENSG00000071242	ENSG00000169032
Uniprot IDs		B7Z3B5 Q15349 X5D337	A4QPA9 B4DFY5 H3BRW9 Q02750
PDB IDs			1S9J 2P55 3DV3 3DY7 3E8N 3EQB 3EQC 3EQD 3EQF 3EQG 3EQH 3EQI 3MBL 3ORN 3OS3 3PP1 3SLS 3V01 3V04 3VVH 3W8Q 3WIG 3ZLS 3ZLW 3ZLX 3ZLY 3ZM4 4AN2 4AN3 4AN9 4ANB 4ARK 4LMN 4MNE 4U7Z 4U80 4U81 5BX0 5EYM 5HZE 5YT3 6NYB 6PP9 6Q0J 6Q0T 6U2G
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?